Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 64

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2018

Summary

According to the recently published report 'Prostate Specific Antigen - Pipeline Review, H1 2018'; Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It is hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum.

The report 'Prostate Specific Antigen - Pipeline Review, H1 2018' outlays comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 2, 1 and 4 respectively.

Similarly, the universities portfolio in Phase II stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone Refractory (Castration Resistant and Androgen-Independent) Prostate Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)

- The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects

- The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Overview
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Companies Involved in Therapeutics Development
Advaxis Inc
Bavarian Nordic A/S
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
NantKwest Inc
OncBioMune Pharmaceuticals Inc
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Drug Profiles
ADXS-PSA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 1 to Inhibit PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonl Antibody to Inhibit PSA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostatac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilimogene galvacirepvec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Castration Resistant Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Dormant Products
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Discontinued Products
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Product Development Milestones
Featured News & Press Releases
Jun 01, 2018: Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting
May 17, 2018: Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer
Apr 02, 2018: Data Highlighting Advaxis ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting
Mar 28, 2018: OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial
Mar 22, 2018: Scientific Review Committee Meets on OncBioMune's Phase 2 Prostate Cancer Clinical Trial
Mar 08, 2018: OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer
Feb 28, 2018: OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas
Feb 26, 2018: OncBioMune Provides Updates on two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
Feb 16, 2018: OncBioMune Provides Update on Market Activity
Feb 05, 2018: OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas
Jan 10, 2018: 70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time
Dec 21, 2017: One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial
Dec 05, 2017: 100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression
Nov 13, 2017: 80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
Sep 19, 2017: Two Abstracts Featuring Advaxis' Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Advaxis Inc, H1 2018
Pipeline by Bavarian Nordic A/S, H1 2018
Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Pipeline by Inspyr Therapeutics Inc, H1 2018
Pipeline by NantKwest Inc, H1 2018
Pipeline by OncBioMune Pharmaceuticals Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Sterile Injectables Market – Analysis By Molecule Type, Drug Type, Indication, Distribution Channel, By Region, By Country (2018 Edition): Forecast to 2023 -- Molecule Type (Biologic, Small Molecule), Drug Type (Monoclonal Antibody, Insulin, Vaccine, Fusion Protein, Immunoglobulin), Indication (Disorders – Oncological, Cardiovascular, Neurological, Infectious, Metabolic, Musculoskeletal), Channel (Hospital Pharmacy, Retail Pharmacy, E-commerce)
    Published: 25-Jun-2018        Price: US 2400 Onwards        Pages: 240
    Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Sterile Injectables Market by Molecule Type (Biologic, Small Molecule),  Drug Type (Monoclonal Antibody, Insulin, Vaccine, Fusion Protein, Immunoglobulin), Indication (Disorders – Oncological, Cardiovascular, Neurological, Infectious, Met......
  • Global Antidiabetic Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 25-Jun-2018        Price: US 3480 Onwards        Pages: 134
    Diabetes mellitus is a kind of chronic comprehensive disease mainly caused by glucose metabolism disorder due to absolute or relative deficiency of insulin or decreased insulin sensitivity of target cells. The occurrence of type 2 diabetes mellitus is a combination of peripheral insulin resistance and ß cell dysfunction. the result of. When diabetes patients undergo diet and exercise therapy and diabetes care education, blood glucose control can still not reach the treatment goals, the need for ......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Antidiabetic Drug Market 2018, Forecast to 2023
    Published: 25-Jun-2018        Price: US 4880 Onwards        Pages: 134
    Diabetes mellitus is a kind of chronic comprehensive disease mainly caused by glucose metabolism disorder due to absolute or relative deficiency of insulin or decreased insulin sensitivity of target cells. The occurrence of type 2 diabetes mellitus is a combination of peripheral insulin resistance and ß cell dysfunction. the result of. When diabetes patients undergo diet and exercise therapy and diabetes care education, blood glucose control can still not reach the treatment goals, the need for ......
  • Global Insulin Drug and Delivery Technologies Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 25-Jun-2018        Price: US 3480 Onwards        Pages: 131
    Insulin is a protein hormone that is used as a medication to treat high blood glucose. This includes in diabetes mellitus type 1, diabetes mellitus type 2, gestational diabetes, and complications of  diabetes such as  diabetic ketoacidosis and hyperosmolar hyperglycemic states. It is also used along with glucose to treat high blood potassium levels. Typically it is given by injection under the skin, but some forms may also be used by injection into a vein or muscle. Scope of the R......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Insulin Drug and Delivery Technologies Market 2018, Forecast to 2023
    Published: 25-Jun-2018        Price: US 4880 Onwards        Pages: 130
    Insulin is a protein hormone that is used as a medication to treat high blood glucose. This includes in diabetes mellitus type 1, diabetes mellitus type 2, gestational diabetes, and complications of  diabetes such as  diabetic ketoacidosis and hyperosmolar hyperglycemic states. It is also used along with glucose to treat high blood potassium levels. Typically it is given by injection under the skin, but some forms may also be used by injection into a vein or muscle. Scope of the R......
  • Global EPA/DHA (Omega 3) Ingredients Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 25-Jun-2018        Price: US 3480 Onwards        Pages: 136
    IOI's range of MARIS OMEGA-3 ingredients helps making great products healthier, offering all the well-documented benefits of EPA and DHA for the cardiovascular and the nervous system. MARIS OMEGA-3 is manufactured "fresh as sushi", making use of innovative production technology to reach lowest oxidation levels. 100 % neutral in taste and smell, MARIS OMEGA-3 provides superior sensory properties and stability for food applications. Scope of the Report: This report focuses on......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) EPA/DHA (Omega 3) Ingredients Market 2018, Forecast to 2023
    Published: 25-Jun-2018        Price: US 4880 Onwards        Pages: 129
    IOI's range of MARIS OMEGA-3 ingredients helps making great products healthier, offering all the well-documented benefits of EPA and DHA for the cardiovascular and the nervous system. MARIS OMEGA-3 is manufactured "fresh as sushi", making use of innovative production technology to reach lowest oxidation levels. 100 % neutral in taste and smell, MARIS OMEGA-3 provides superior sensory properties and stability for food applications. Scope of the Report: This report focuses on......
  • Global Erythropoietin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Jun-2018        Price: US 3480 Onwards        Pages: 136
    Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Erythropoietin Market 2018, Forecast to 2023
    Published: 23-Jun-2018        Price: US 4880 Onwards        Pages: 131
    Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs